AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06293742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally.
Study NCT06293742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered orally.
Study NCT06293742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin will be administered orally.
Study NCT06293742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally.
Study NCT06514287 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized intervention
Description: It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
Study NCT04483414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga PSMA-11 injection
Description: Injection of 68Ga PSMA-11
Study NCT04483414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after 68Ga PSMA-11 injection
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study NCT05449899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
Study NCT05846750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression
Study NCT05846750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression
Study NCT05194514 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SherpaPak™ Device
Description: The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
Study NCT05194514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold Storage
Description: FDA-approved method for organ procurement
Study NCT06144255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken.
Study NCT04821063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357 10 mg/mL
Description: Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
Study NCT04821063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357 10 mg/mL
Description: Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
Study NCT04821063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose: 20 mL; Dosage form: suspension; Route of administration: oral
Study NCT04821063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Dose: 400 mg; Dosage form: tablet; Route of administration: oral
Study NCT04821063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 30 mL; Dosage form: suspension; Route of administration: oral
Study NCT05181267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
Study NCT06435013 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
Study NCT05201092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Lu AG06466
Description: \[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
Study NCT04960215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
Study NCT04960215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A soft gelatin capsule containing soy oil, 5 capsules a day.
Study NCT05671081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
Study NCT05671081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
Study NCT05671081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcotic Analgesics
Description: patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
Study NCT06047405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Average Volume-Assured Pressure Support (AVAPS)
Description: A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
Study NCT06047405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)
Description: A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
Study NCT05246254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index scale
Description: There are clinically common scales for assessing weakness and delirium.
Study NCT05463965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QM1114-DP
Description: Intramuscular injection
Study NCT05463965 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Intramuscular injection
Study NCT05463965 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT05146778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free anesthesia
Description: OFA group will be sedated using dexmedetomidine and lidocaine.
Study NCT05146778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional opioid-based anesthesia
Description: Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
Study NCT05925192 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: N/A - observational study
Study NCT04268693 — intervention group
Intervention type: OTHER
Intervention: urine collection
Description: Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthened SBCC
Description: Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
Study NCT04872088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preventive nutritional supplement
Description: Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~- \[6-17\]months old children diagnosed as non-wasted (MUAC>=125mm)
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family MUAC
Description: MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family.
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active screening by NASGs
Description: Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled.
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified followup of children with wasting referred to and enrolled in CMAM treatment
Description: NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention
Description: NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
Study NCT04872088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking demonstrations
Description: NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
Study NCT06221176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being Brave
Description: Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
Study NCT06204952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)
Description: In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
Study NCT06204952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
Study NCT05313659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
Study NCT05460403 — intervention group
Intervention type: RADIATION
Intervention: Adjuvant Radiotherapy
Description: Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
Study NCT00105599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: End of life care coordination
Study NCT00105599 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FairCare System
Study NCT05865132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 120mg/125mg po qd on day 1 to 21, every 28 days
Study NCT05865132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg/40mg po qd on day 1 to 28, every 28 days
Study NCT06018727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 20 mg capsule will be administered orally.
Study NCT06018727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: Yohimbine 20 mg capsule will be administered orally.
Study NCT06018727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebos will be administered orally.
Study NCT04715165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: USG-STAP with bupivacaine and dexmedetomidine
Description: Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
Study NCT04715165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IP bupivacaine and dexmedetomidine
Description: Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
Study NCT06380673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of cow's milk in decreasingly heated forms
Description: Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Study NCT06380673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of heated cow's milk
Description: Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Study NCT06380673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Healthy subjects undergo no intervention.
Study NCT04720872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and vestibular rehabilitation treatment
Description: The experimental group received manual therapy and vestibular rehabilitation treatment.
Study NCT06445933 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
Study NCT06445933 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06313463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrellizumab + Capecitabine
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
Study NCT06313463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Capecitabine
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
Study NCT05577416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Patients will undergo stereotactic biopsy by craniotomy or burr hole.
Study NCT05577416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Safusidenib Erbumine
Description: Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
Study NCT05577416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (maximal resection)
Description: Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
Study NCT05577416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Safusidenib Erbumine
Description: Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
Study NCT04833374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
Study NCT04833374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
Study NCT05619328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B combination tablet
Description: Once daily, with some liquid with or after a meal
Study NCT05619328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Once daily, with some liquid with or after a meal
Study NCT05494528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
Study NCT05494528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg once per day
Study NCT05346796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan-Personal Health Record (SCP-PHR)
Description: The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
Study NCT04782284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive swallowing rehabilitation
Description: The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
Study NCT04782284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing education
Description: The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
Study NCT05185063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care blood test
Description: The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
Study NCT05075278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: A survey will be completed by the participants at the conclusion of each day.
Study NCT05075278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: A survey will be completed by the participants at the conclusion of each day.
Study NCT05799846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention
Study NCT05799846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity